Eli Lilly’s $12.8 billion obesity bet faces a new Medicare coverage test

Eli Lilly’s obesity push is entering a phase that matters as much to investors as it does to patients. On July 1, 2026, the U.S. Centers for Medicare & Medicaid Services will begin the Medicare GLP-1 Bridge, a short-term demonstration that will provide eligible Medicare Part D beneficiaries access to certain GLP-1 drugs through the end of December 31, 2027. The program’s structure is meant to create a real-world test of how much utilization could rise when Medicare, historically constrained on covering obesity treatment, expands access under a defined set of rules.

For Lilly, that makes Medicare less of a backdrop and more of an input into growth math. TheStreet said the company’s obesity franchise is already delivering massive run-rate results, reporting Mounjaro sales of almost $8.7 billion in the first quarter of 2026 and Zepbound sales of about $4.1 billion, for combined quarterly sales of more than $12.8 billion. In that context, Medicare becomes a key determinant of whether the addressable market stays on its current trajectory or needs to be revised downward if coverage mechanisms prove more limited than investors assume.

The Bridge is also being designed to isolate variables for CMS. According to CMS, the Medicare GLP-1 Bridge operates outside the standard Medicare Part D coverage and payment flow, meaning Part D sponsors do not carry risk for drugs furnished under the demonstration. CMS will use a single central processor in 2026 to manage prior authorization, claims adjudication, and payments to pharmacies. CMS also set a $50 copay for eligible beneficiaries under the demonstration, and it states the Part D deductible will not apply for those drugs.

What counts as “eligible” on the drug side will influence which products benefit first. TheStreet reported that CMS identified Bridge-eligible therapies including Eli Lilly’s Foundayo and Zepbound in its KwikPen form, plus Novo Nordisk’s Wegovy, while omitting Zepbound’s single-dose vial and single-dose pen formulations. In plain terms, GLP-1s are a class of medicines that affect appetite and metabolism, and Lilly’s lineup spans both injectable obesity treatment (Zepbound) and an oral GLP-1 receptor agonist concept (Foundayo), depending on product and approval status.

Even if the Bridge looks generous on paper, the program is not being presented as an automatic expansion of long-term coverage. TheStreet warned that CMS has not articulated the level of long-term involvement, potential policy implications, or how Bridge results will inform broader Medicare decisions. CMS does say it will collect additional data on utilization to share with Part D plan sponsors ahead of potential implementation of its broader BALANCE framework.

CMS has been preparing that next step as part of a wider affordability and access effort for GLP-1s. In a March 2026 update, CMS said the BALANCE model is expected to launch in Medicare Part D in January 2027, while the agency also described the Bridge as a “payment demonstration” beginning in July 2026 to serve as a bridge toward the model. Lilly, in turn, published implementation details around the CMMI BALANCE model, saying Zepbound and other qualifying Lilly medicines, along with its oral obesity option if approved, would be available through Medicare Part D participating plans beginning January 1, 2027, with most beneficiaries having out-of-pocket costs capped at $50 per month after the deductible.

The market implication is straightforward but not fully knowable yet: the Bridge can announcement whether government coverage can unlock sustained demand at scale, which would support higher obesity-industry expectations, or it could reveal friction points that limit utilization even with a capped copay. TheStreet framed this as “the $12.8 billion question” for Lilly’s obesity thesis, pointing out that even slight shifts in access assumptions could matter.

What to watch next is not just whether beneficiaries can start filling prescriptions, but how quickly utilization and expenditures rise during 2026 and whether CMS and regulators can translate Bridge data into the broader BALANCE rollout without changing the affordability terms that make access feasible for Medicare patients.